ad shares: at present, direct supply of Vanke, poly and other major real estate accounts for more than 80%
Ad shares ( Yonggao Co.Ltd(002641) ) said in the newly disclosed record of investor relations activities that since the Evergrande incident, the company has been more cautious about the direct supply business of real estate. The real estate business mainly focuses on the direct distribution of large-scale, state-owned companies with good assets, and the real estate customers are relatively concentrated. At present, Vanke, poly, China Merchants, China shipping Xuhui and other major real estate direct supply accounts for more than 80%, and the scale of other real estate businesses is small.
Bece Legend Group Co.Ltd(000803) : the net profit in 2021 increased by 78% year-on-year, and it is planned to turn 10 to 4
Bece Legend Group Co.Ltd(000803) ( Bece Legend Group Co.Ltd(000803) ) disclosed the annual report of 2021 on March 4. During the reporting period, the company achieved an operating revenue of 827 million yuan, a year-on-year increase of 138.33%; The net profit was 80.51 million yuan, a year-on-year increase of 78.38%; The basic earnings per share is 0.39 yuan. The company plans to increase 4 shares for every 10 shares to all shareholders with capital reserve.
China Meheco Group Co.Ltd(600056) : even if the cooperation is successful, it is estimated that the scale of covid-19 therapeutic drug business accounts for a small proportion of the company’s overall business
China Meheco Group Co.Ltd(600056) ( China Meheco Group Co.Ltd(600056) ) on March 4, the company issued a risk warning announcement. The company was concerned about the recent rumors of cooperation between the company and covid-19 virus treatment drugs, a multinational pharmaceutical company. After verification by the company, relevant matters are under communication and negotiation, but there are still uncertainties about the specific terms of the agreement and whether it can be signed smoothly. In addition, even if the cooperation is carried out smoothly, the final use and sales of relevant drugs are also affected by factors such as epidemic prevention and control, there is great uncertainty, and it is expected that the relevant business scale accounts for a small proportion of the company’s overall business volume, which has no significant impact on the company’s recent operating performance.
Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) attention letter: it is required to list the corresponding end customers of azvudine API
Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) ( Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) ) received the attention letter from Shenzhen Stock Exchange. It is required to list the product name and corresponding end customers of azvudine API produced by the company, and explain the ownership of relevant products and corresponding end drugs. List the current production capacity of relevant products of the company, product production and sales volume, operating revenue and proportion achieved in recent one year and one period, and orders on hand; Explain the impact of the construction progress, investment scale, production arrangement and expected production capacity of the company’s new azvudine API production line on the production of other existing products of the company; Explain the market competition pattern in combination with the market share and market demand of the company’s related products and corresponding terminal drugs, as well as the current R & D, listing and sales of similar indications at home and abroad; Explain whether the company’s reply on the “interactive easy” platform hypes the concept of hot spots and cooperates with the reduction of shareholders’ holdings.
Jiangxi Zhengbang Technology Co.Ltd(002157) attention letter: it is required to explain the background, necessity and rationality of selling part of the equity of the feed company
Attention letter from Shenzhen Stock Exchange. Recently, some market media released relevant reports such as “online transmission Jiangxi Zhengbang Technology Co.Ltd(002157) handling breeding loans in the name of employees” and “Zhengbang group applying for bankruptcy”, which questioned the capital stability of the company and its controlling shareholders. Shenzhen stock exchange requires the company to explain the background, necessity and rationality of selling part of the equity of the feed company, and the possible impact on the subsequent operation and performance of the company.
Asymchem Laboratories (Tianjin) Co.Ltd(002821) : it is proposed to invest 3 billion yuan to build a biological drug cdmo R & D and commercial production base
Asymchem Laboratories (Tianjin) Co.Ltd(002821) ( Asymchem Laboratories (Tianjin) Co.Ltd(002821) ) it was announced on March 4 that the company signed an investment agreement with Shanghai Industrial Comprehensive Development Zone Co., Ltd. on the same day. The company invested in the newly established wholly-owned subsidiary and planned to invest 3 billion yuan of its own or self raised funds to build a biological drug cdmo R & D and commercial production base in Fengxian, Shanghai.
Zanyu Technology Group Co.Ltd(002637) : Indonesia DMO policy has uncertain impact on the company’s profits
Zanyu Technology Group Co.Ltd(002637) ( Zanyu Technology Group Co.Ltd(002637) ) on March 4, it was announced that the implementation scope of DMO policy of Indonesian government was further expanded, which had an adverse impact on the export of dukuda products, the subsidiary. The company will actively apply for export license and strive to resume normal export as soon as possible; Actively communicate with customers and appropriately adjust the delivery date without affecting customers’ operation.
